DOES ANTIPLATELET THERAPY INCREASE THE BLEEDING EVENTS AMONG PATIENTS WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANT IN REAL WORLD?

DOES ANTIPLATELET THERAPY INCREASE THE BLEEDING EVENTS AMONG PATIENTS WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANT IN REAL WORLD?

A consecutive cohort of 1585 patients (1025 were men, mean age was 70±11 years, mean BMI was 23.5, Paroxysmal AF 65%, Persistent AF 13.8%, Long standing persistent AF 21%, mean creatinine clearance was 76.6ml/min, mean CHADS score was 1.7 point, mean HASBLED score was 1.1 point, Dabigatran N=1122, R...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2015-03, Vol.65 (10), p.A351-A351
Hauptverfasser: Okamoto, Yoji, Fujii, Satoki, Ozaki, Masatomo, Yoshino, Mitsuru, Ohashi, Noriyuki, Tasaka, Hiroshi, Kadota, Kazushige, Mitsudo, Kazuaki
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
Cardiology
Cardiovascular
Drug therapy
Internal Medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A consecutive cohort of 1585 patients (1025 were men, mean age was 70±11 years, mean BMI was 23.5, Paroxysmal AF 65%, Persistent AF 13.8%, Long standing persistent AF 21%, mean creatinine clearance was 76.6ml/min, mean CHADS score was 1.7 point, mean HASBLED score was 1.1 point, Dabigatran N=1122, Ribaroxaban N=266, Apixaban N=197) was studied.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(15)60351-5